ASCO GI

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

ASCO update on lymphoma

s concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed.

متن کامل

ASCO update: lung cancer

In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new c...

متن کامل

American Society of Clinical Oncology's 2008 Gastrointestinal Cancers Symposium (ASCO GI), January 25-27, 2008, Orlando, Florida.

Should combination or sequential strategies be preferred in colorectal cancer? This was the subject of an evening debate featured at the ASCO GI meeting. The controversy had been sparked by studies published recently in the same issue of The Lancet. The first – the Focus study (Seymour et al., 2007. Lancet 370, 143–152) which compared upfront combination treatment with 5FU (fluorouracil, irinot...

متن کامل

ASCO-update: gastrointestinal tumors

A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before co...

متن کامل

Roche Investor Relations ASCO

 Abstract 9025 Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster Board #351  Abstract 9064 Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). Poster Board #390  Abstract 9092 Atezolizumab...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cancéro digest

سال: 2010

ISSN: 1953-5171,1953-5171

DOI: 10.4267/2042/30743